Valuation : Insulet Corporation

Market Cap 9.94B 8.53B 8.01B 7.32B 13.81B 948B 13.87B 94.8B 36.74B 478B 37.34B 36.53B 1,585B P/E 2026 *
23.4x
P/E 2027 * 18.8x
Enterprise Value 9.99B 8.58B 8.05B 7.35B 13.88B 953B 13.94B 95.28B 36.92B 481B 37.52B 36.71B 1,593B EV / Sales 2026 *
3.04x
EV / Sales 2027 * 2.57x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day+0.23%
1 week-5.37%
Current month-13.29%
1 month-12.18%
3 months-6.78%
6 months-42.99%
Current year-49.56%
1 week 141.23
Extreme 141.23
151.75
1 month 126.4
Extreme 126.4
172.92
Current year 126.4
Extreme 126.4
299.8
1 year 126.4
Extreme 126.4
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 27/04/2025
Director of Finance/CFO 53 29/09/2025
Compliance Officer 50 30/11/2022
Director TitleAgeSince
Chairman 61 31/12/2018
Director/Board Member 61 26/07/2015
Director/Board Member 59 09/08/2017
Date Insider Type Main position Quantity % Market Cap.
21/08/26 Buy

Chief Executive Officer

1,100 0.0016%
01/08/26 Tax

Head of Human Resources

-244 0.0003%
01/07/26 Free

Director

1,355 0.0019%
Change 5-day change 1-year change 3-year change Capi.($)
+0.23%-5.37%-56.79%-21.65% 9.94B
-1.75%-0.29%-13.29%+9.49% 197B
+0.97%-2.24%-0.17%+11.96% 118B
-0.08%+3.37%+13.15%+82.63% 62.55B
-2.00%-3.74%+27.02%+53.48% 52.4B
+0.23%+1.39%-1.99%-32.07% 51.81B
-0.22%-1.02%+16.87%-11.71% 33.57B
-2.97%+1.98% - - 30.34B
+0.41%-0.81%+43.12%-11.13% 24.63B
-0.47%+3.56%-3.25%+19.21% 23.81B
Average -0.74%+0.06%+2.74%+11.14% 60.43B
Weighted average by Cap. -1.05%-0.08%+0.83%+15.97%

Financials

2026 *2027 *
Net sales 3.29B 2.82B 2.65B 2.42B 4.57B 314B 4.59B 31.34B 12.15B 158B 12.34B 12.08B 524B 3.74B 3.21B 3.02B 2.75B 5.2B 357B 5.22B 35.7B 13.83B 180B 14.06B 13.75B 597B
Net income 427M 366M 344M 314M 592M 40.69B 595M 4.07B 1.58B 20.53B 1.6B 1.57B 67.99B 535M 459M 431M 394M 743M 51.06B 747M 5.1B 1.98B 25.76B 2.01B 1.97B 85.31B
Net Debt 49.62M 42.59M 39.98M 36.51M 68.91M 4.73B 69.24M 473M 183M 2.39B 186M 182M 7.91B -322M -277M -260M -237M -448M -30.75B -450M -3.07B -1.19B -15.51B -1.21B -1.18B -51.38B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
26/08/26 US$143.38 +0.23% 1,423,995
25/08/26 US$143.05 -1.63% 1,925,455
24/08/26 US$145.42 -1.85% 1,568,557
21/08/26 US$148.16 +0.88% 903,610
20/08/26 US$146.87 -3.06% 1,212,723
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
143.38USD
Average target price
171.91USD
Spread / Average Target
+19.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock